EGFR突变腺癌转化为小细胞肺癌及其他神经内分泌癌：临床结局

Marcoux等人（周五，）研究了该问题。

www.synapsesocial.com/papers/69dbdfd59e6f14d6f1684957 — DOI: https://doi.org/10.1200/jco.18.01585

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma· 2017 · 632 citations
2. Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors· 2011 · 3,547 citations
3. Activity of docetaxel (Taxotere) in small cell lung cancer· 1994 · 139 citations
4. A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer· 1998 · 185 citations
5. Delay of treatment change after objective progression on first‐line erlotinib in epidermal growth factor receptor‐mutant lung cancer· 2015 · 53 citations